$6 Million Trade Highlights Pfizer Inc. (PFE) Options Feeding Frenzy

Pfizer Inc. (NYSE:PFE) options traders are making major moves amid today's tax inversion hoopla

Apr 5, 2016 at 3:36 PM
facebook X logo linkedin


Pfizer Inc. (NYSE:PFE) is up 1.8% at $31.28, with today's volume nearly doubling its previous annual high, amid the potentially damaging news surrounding its merger with Allergan plc Ordinary Shares (NYSE:AGN). In fact, Reuters reported this afternoon that PFE is now leaning toward walking away from the deal, and options volume is surging as a result.

PFE's 30-day at-the-money implied volatility has jumped almost 16% to 19.5%, reflecting increased volatility expectations. Further, options volume is four times the expected intraday total, and on pace to surpass the Aug. 4 high, thanks to several large-block trades.

According to the International Securities Exchange (ISE), it looks like one trader simultaneously bought to open identical 21,000-contract blocks of the January 2017 28-strike put and 32-strike call for $1.38 and $1.52 per contract, respectively. The volatility strategy -- known as a "long strangle" -- was opened for a net debit of $2.90 per pair of contracts, or nearly $6.1 million (net debit * 100 shares per contract * number of spreads). The buyer will make money the lower PFE falls beneath $25.10 (put strike minus net debit) or rallies north of $34.90 (call strike plus net debit) by January options expiration.

Elsewhere, a sale of 10,000 Sept. 30 calls crossed earlier, as well as a sale of nearly 11,500 January 2017 30-strike calls. It's possible these were traders cashing out of their positions amid today's rally in the shares, according to Trade-Alert

Before today, it had been PFE puts that were in high demand. The stock's 10-day put/call volume ratio at the ISE, Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) comes in at 1.10 -- in the 87th percentile of its annual range. However, options were popular on both sides of the aisle, as put and call open interest are at annual highs.

Pfizer Inc.'s (NYSE:PFE) rally has it on pace for its best finish in months, with help from news that the company's psoriatic arthritis drug, tofacitinib, met its main goals in a phase 3 study. However, the stock could run into a wall in the $31.50-$32 area, which acted as support in the latter half of 2015.  

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI